Tulin Budak
Expertise in
31
conditions

Dr. Tulin Budak

Hematology | Oncology
2 Cooper Plaza, 
Camden, NJ 
Accepting New Patients
Offers Telehealth
39 Years of Experience
Expertise in
31
conditions
2 Cooper Plaza, 
Camden, NJ 

Overview

Tulin Budak is a Hematologist and an Oncologist practicing medicine in Camden, New Jersey. She has been practicing medicine for over 39 years.

Dr. Budak is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), Deep Vein Thrombosis, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Budak is board certified in American Board Of Internal Medicine,Medical Oncology , 2012, American Board Of Internal Medicine,Hematology , 2012, and American Board Of Internal Medicine,Internal Medicine , 2012. She is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 3 clinical trials. Dr. Budak is currently accepting new patients.

Graduate Institution

Hacettepe University Medical School, 1987

Residency

Hacettepe University Medical School,Internal Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine,Medical Oncology , 2012
American Board Of Internal Medicine,Hematology , 2012
American Board Of Internal Medicine,Internal Medicine , 2012

Fellowships

Thomas Jefferson University,Hematology and Medical Oncology,2012
University of Medicine and Dentistry - Robert Wood Johnson University Hospital,Hematology and Medical Oncology,2010

Hospital Affiliations

Cooper University Hospital
Inspira Medical Center Mullica Hill
Virtua Mount Holly Hospital

Languages Spoken

English
Turkish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Guardian Life Insurance Company
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

MD Anderson Cancer Center at Cooper - Camden
2 Cooper Plaza, Camden, NJ 08103
Other Locations
Cooper and Inspira Cardiac Care at Voorhees Campus
900 Centennial Blvd., Building 2, Suite 201, Voorhees, NJ 08043
MD Anderson Cancer Center at Cooper
501 Fellowship Road, Suite 102, Mount Laurel, NJ 08054
MD Anderson Cancer Center at Cooper
2 Cooper Plaza, 4th Floor, Camden, NJ 08103
Md Anderson Cancer Center Cooper
2 Cooper Plz, Camden, NJ 08103

Additional Areas of Focus

Dr. Budak has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Antiphospholipid Syndrome
Metastatic Uveal Melanoma
Leukemia
Multiple Myeloma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
View 2 Less Clinical Trials

34 Total Publications

The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm.
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm.
Journal: Expert opinion on biological therapy
Published: December 25, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Expertise in
12
conditions
Dr. Janet L. Kwiatkowski
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (4.3 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Janet Kwiatkowski is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Kwiatkowski is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Bone Marrow Transplant, and Splenectomy.

Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Expertise in
13
conditions
Dr. John M. Maris
Hematology | Oncology
Referral may be required

Office

3500 Civic Center Blvd, 
Philadelphia, PA 
 (4.2 miles away)
215-590-3025
Languages Spoken:
English

John Maris is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Maris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Rhabdomyosarcoma.

Expertise in
17
conditions
Dr. Stephan A. Grupp
Hematology | Oncology
Expertise in
17
conditions
Dr. Stephan A. Grupp
Hematology | Oncology
Referral may be required

Office

3401 Civic Center Blvd, 
Philadelphia, PA 
 (4.3 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Stephan Grupp is a Hematologist and an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Grupp is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hepatic Venoocclusive Disease with Immunodeficiency, Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Tulin Budak

How do I make an appointment with Dr. Tulin Budak?

You can book an appointment with Dr. Tulin Budak by calling their office at 855-632-2667. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tulin Budak a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tulin Budak is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tulin Budak specialize in?

While Dr. Tulin Budak is a Hematology, they have specific expertise in Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), and Deep Vein Thrombosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Tulin Budak participate in research or clinical trials?

Yes. Dr. Tulin Budak has published 34 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Tulin Budak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tulin Budak accept my insurance?

Dr. Tulin Budak accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 855-632-2667 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Budak's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 102 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile